ANAPC10: A Potential Drug Target and Biomarker for Anaplastic Leukemia

Target Name: ANAPC10

NCBI ID: G10393

ANAPC10

ANAPC10: A Potential Drug Target and Biomarker for Anaplastic Leukemia

Anaplastic leukemia (ANL) is a type of cancer that arises from the stem cells of the bone marrow. It is a rare and aggressive cancer that affects patients worldwide, with poor prognosis and limited treatment options. The ANAPC10 gene has been identified as a potential drug target and biomarker for ANL. In this article, we will discuss the ANAPC10 gene, its function, and its potential as a drug target and biomarker for ANL.

ANAPC10 gene and its function

The ANAPC10 gene is located on chromosome 17 at position 17q21. It is a gene that encodes a protein known as p120 Anaplastic Leukemia (p120-AL) viral protein (p120-ALPV). The p120-ALPV protein is a viral envelope protein that is present in the virus that causes human herpesvirus 8 (HHV-8). HHV-8 is a member of the herpesviridae family and is considered to be a potential cancer-causing agent.

The p120-ALPV protein has been shown to play a role in the development and progression of ANL. Studies have shown that p120-ALPV is overexpressed in ANL cells and that its overexpression is associated with poor prognosis. Additionally, p120-ALPV has been shown to promote the growth and survival of ANL cells in a cell-based assay.

ANAPC10 as a drug target

The ANAPC10 gene has been identified as a potential drug target for ANL because of its involvement in the development and progression of this disease. By targeting the p120-ALPV protein, drugs can potentially inhibit its function and reduce the growth and survival of ANL cells.

One approach to targeting p120-ALPV is through the use of small molecule inhibitors. These inhibitors can be designed to specifically bind to the protein and prevent its function. One such inhibitor is currently in clinical trials for the treatment of ANL.

ANAPC10 as a biomarker

In addition to its potential as a drug target, ANAPC10 has also been identified as a potential biomarker for ANL. The p120-ALPV protein is expressed in high levels in ANL cells, and its expression is associated with the poor prognosis of ANL.

Studies have shown that the expression of p120-ALPV is significantly correlated with the diagnosis of ANL. Additionally, levels of p120-ALPV have been shown to be elevated in ANL patient samples, and that these levels are associated with poor prognosis.

In conclusion, the ANAPC10 gene has been identified as a potential drug target and biomarker for ANL. The p120-ALPV protein has been shown to play a role in the development and progression of ANL, and small molecule inhibitors have been shown to be effective in targeting its function. Further research is needed to confirm its potential as a drug target and biomarker for ANL.

Protein Name: Anaphase Promoting Complex Subunit 10

Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains

The "ANAPC10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets